A Case of Adult-Onset Still’s Disease Caused by a Novel Splicing Mutation in TNFAIP3 Successfully Treated With Tocilizumab

TNFAIP3 encodes the NF-κB regulatory protein A20. High-penetrance heterozygous mutations in TNFAIP3 cause a haploinsufficiency of A20 (HA20), inadequate inhibition of NF-κB pathway, and an early onset autoinflammatory disorder. However, the clinical phenotype of patients with HA20 varies greatly and...

Full description

Bibliographic Details
Main Authors: Dylan Lawless, Shelly Pathak, Thomas Edward Scambler, Lylia Ouboussad, Rashida Anwar, Sinisa Savic
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-07-01
Series:Frontiers in Immunology
Subjects:
A20
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.01527/full
id doaj-c4bdb14439b64fcc93b9b972d49c44cf
record_format Article
spelling doaj-c4bdb14439b64fcc93b9b972d49c44cf2020-11-24T21:12:29ZengFrontiers Media S.A.Frontiers in Immunology1664-32242018-07-01910.3389/fimmu.2018.01527372267A Case of Adult-Onset Still’s Disease Caused by a Novel Splicing Mutation in TNFAIP3 Successfully Treated With TocilizumabDylan Lawless0Shelly Pathak1Thomas Edward Scambler2Lylia Ouboussad3Rashida Anwar4Sinisa Savic5Sinisa Savic6Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Wellcome Trust Brenner Building, St James’s University Hospital, Leeds, United KingdomLeeds Institute of Rheumatic and Musculoskeletal Medicine, Wellcome Trust Brenner Building, St. James’s University Hospital, Leeds, United KingdomLeeds Institute of Rheumatic and Musculoskeletal Medicine, Wellcome Trust Brenner Building, St. James’s University Hospital, Leeds, United KingdomLeeds Institute of Rheumatic and Musculoskeletal Medicine, Wellcome Trust Brenner Building, St. James’s University Hospital, Leeds, United KingdomLeeds Institute of Biomedical and Clinical Sciences, University of Leeds, Wellcome Trust Brenner Building, St James’s University Hospital, Leeds, United KingdomLeeds Institute of Rheumatic and Musculoskeletal Medicine, Wellcome Trust Brenner Building, St. James’s University Hospital, Leeds, United KingdomDepartment of Clinical Immunology and Allergy, St. James’s University Hospital, Leeds, United KingdomTNFAIP3 encodes the NF-κB regulatory protein A20. High-penetrance heterozygous mutations in TNFAIP3 cause a haploinsufficiency of A20 (HA20), inadequate inhibition of NF-κB pathway, and an early onset autoinflammatory disorder. However, the clinical phenotype of patients with HA20 varies greatly and clinical diagnoses prior to establishing the genetic cause, included both autoimmune and autoinflammatory conditions. Here, we present the first patient with HA20, who was previously diagnosed with AOSD but was later found to have a novel heterozygous variant in TNFAIP3 and who was successfully treated with anti-IL6 receptor biologic tocilizumab (RoActemra). We discovered a novel heterozygous mutation in TNFAIP3 c.1906C>T, not previously found in ExAC database. Further analysis shows that this single-nucleotide variant at the terminal residue of TNFAIP3 exon 7 produces an alternatively spliced mRNA resulting in p.His636fsTer1. Additional genetic analysis of family members shows that this variant does segregate with the inflammatory clinical phenotypes. Subsequent functional test show that NF-κB activation, measured as intracellular phosphorylation of p65 in CD14 + monocytes, was more enhanced in the patient compared with healthy controls (HC) following stimulation with LPS. This was associated with higher production of inflammatory cytokines by the patients PBMC in response to LPS and ATP and enhanced activation of NLRP3 inflammasome complex. Furthermore, increased activation of NLRP3 inflammasome was evident systemically, since we detected higher levels of ASC specks in patients’ sera compared with HC. Finally, we used population genetics data from GnomAD to construct a map of both genetic conservation and most probable disease-causing variants in TNFAIP3 which might be found in future cases of HA20.https://www.frontiersin.org/article/10.3389/fimmu.2018.01527/fullTNFAIP3A20AOSDtocilizumabautoinflammatory
collection DOAJ
language English
format Article
sources DOAJ
author Dylan Lawless
Shelly Pathak
Thomas Edward Scambler
Lylia Ouboussad
Rashida Anwar
Sinisa Savic
Sinisa Savic
spellingShingle Dylan Lawless
Shelly Pathak
Thomas Edward Scambler
Lylia Ouboussad
Rashida Anwar
Sinisa Savic
Sinisa Savic
A Case of Adult-Onset Still’s Disease Caused by a Novel Splicing Mutation in TNFAIP3 Successfully Treated With Tocilizumab
Frontiers in Immunology
TNFAIP3
A20
AOSD
tocilizumab
autoinflammatory
author_facet Dylan Lawless
Shelly Pathak
Thomas Edward Scambler
Lylia Ouboussad
Rashida Anwar
Sinisa Savic
Sinisa Savic
author_sort Dylan Lawless
title A Case of Adult-Onset Still’s Disease Caused by a Novel Splicing Mutation in TNFAIP3 Successfully Treated With Tocilizumab
title_short A Case of Adult-Onset Still’s Disease Caused by a Novel Splicing Mutation in TNFAIP3 Successfully Treated With Tocilizumab
title_full A Case of Adult-Onset Still’s Disease Caused by a Novel Splicing Mutation in TNFAIP3 Successfully Treated With Tocilizumab
title_fullStr A Case of Adult-Onset Still’s Disease Caused by a Novel Splicing Mutation in TNFAIP3 Successfully Treated With Tocilizumab
title_full_unstemmed A Case of Adult-Onset Still’s Disease Caused by a Novel Splicing Mutation in TNFAIP3 Successfully Treated With Tocilizumab
title_sort case of adult-onset still’s disease caused by a novel splicing mutation in tnfaip3 successfully treated with tocilizumab
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2018-07-01
description TNFAIP3 encodes the NF-κB regulatory protein A20. High-penetrance heterozygous mutations in TNFAIP3 cause a haploinsufficiency of A20 (HA20), inadequate inhibition of NF-κB pathway, and an early onset autoinflammatory disorder. However, the clinical phenotype of patients with HA20 varies greatly and clinical diagnoses prior to establishing the genetic cause, included both autoimmune and autoinflammatory conditions. Here, we present the first patient with HA20, who was previously diagnosed with AOSD but was later found to have a novel heterozygous variant in TNFAIP3 and who was successfully treated with anti-IL6 receptor biologic tocilizumab (RoActemra). We discovered a novel heterozygous mutation in TNFAIP3 c.1906C>T, not previously found in ExAC database. Further analysis shows that this single-nucleotide variant at the terminal residue of TNFAIP3 exon 7 produces an alternatively spliced mRNA resulting in p.His636fsTer1. Additional genetic analysis of family members shows that this variant does segregate with the inflammatory clinical phenotypes. Subsequent functional test show that NF-κB activation, measured as intracellular phosphorylation of p65 in CD14 + monocytes, was more enhanced in the patient compared with healthy controls (HC) following stimulation with LPS. This was associated with higher production of inflammatory cytokines by the patients PBMC in response to LPS and ATP and enhanced activation of NLRP3 inflammasome complex. Furthermore, increased activation of NLRP3 inflammasome was evident systemically, since we detected higher levels of ASC specks in patients’ sera compared with HC. Finally, we used population genetics data from GnomAD to construct a map of both genetic conservation and most probable disease-causing variants in TNFAIP3 which might be found in future cases of HA20.
topic TNFAIP3
A20
AOSD
tocilizumab
autoinflammatory
url https://www.frontiersin.org/article/10.3389/fimmu.2018.01527/full
work_keys_str_mv AT dylanlawless acaseofadultonsetstillsdiseasecausedbyanovelsplicingmutationintnfaip3successfullytreatedwithtocilizumab
AT shellypathak acaseofadultonsetstillsdiseasecausedbyanovelsplicingmutationintnfaip3successfullytreatedwithtocilizumab
AT thomasedwardscambler acaseofadultonsetstillsdiseasecausedbyanovelsplicingmutationintnfaip3successfullytreatedwithtocilizumab
AT lyliaouboussad acaseofadultonsetstillsdiseasecausedbyanovelsplicingmutationintnfaip3successfullytreatedwithtocilizumab
AT rashidaanwar acaseofadultonsetstillsdiseasecausedbyanovelsplicingmutationintnfaip3successfullytreatedwithtocilizumab
AT sinisasavic acaseofadultonsetstillsdiseasecausedbyanovelsplicingmutationintnfaip3successfullytreatedwithtocilizumab
AT sinisasavic acaseofadultonsetstillsdiseasecausedbyanovelsplicingmutationintnfaip3successfullytreatedwithtocilizumab
AT dylanlawless caseofadultonsetstillsdiseasecausedbyanovelsplicingmutationintnfaip3successfullytreatedwithtocilizumab
AT shellypathak caseofadultonsetstillsdiseasecausedbyanovelsplicingmutationintnfaip3successfullytreatedwithtocilizumab
AT thomasedwardscambler caseofadultonsetstillsdiseasecausedbyanovelsplicingmutationintnfaip3successfullytreatedwithtocilizumab
AT lyliaouboussad caseofadultonsetstillsdiseasecausedbyanovelsplicingmutationintnfaip3successfullytreatedwithtocilizumab
AT rashidaanwar caseofadultonsetstillsdiseasecausedbyanovelsplicingmutationintnfaip3successfullytreatedwithtocilizumab
AT sinisasavic caseofadultonsetstillsdiseasecausedbyanovelsplicingmutationintnfaip3successfullytreatedwithtocilizumab
AT sinisasavic caseofadultonsetstillsdiseasecausedbyanovelsplicingmutationintnfaip3successfullytreatedwithtocilizumab
_version_ 1716750770549817344